Antithrombin-III for Patients With Hepatic Veno-occlusive Diseases Following Hematopoietic Stem Cell Transplantation

Key facts

Sponsor

Seoul National University Hospital

Principal Investigator

Hyoung Jin Kang, MD, Ph.D

Seoul National University Hospital

Intervention

Freeze-dried Concentrated Human Antithrombin Ⅲ 500 IU(drug)

Enrollment

32 target

Eligibility

65 years · All sexes

Timeline

2013 – 2021

Study locations (1)

• Seoul National University Hospital, Seoul, Chongno-gu, South Korea

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Hepatic veno-occlusive disease

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT05987124
  Defibrotide Dose-escalation for SOS Post-HSCT
  New York Medical College
• RECRUITINGNCT06715046
  Cell Free DNA Profiling As a Tool to Monitor Clinically-Relevant Events in Allogeneic Hematopoietic Stem Cell Transplantation
  University of Turin, Italy
• RECRUITINGNCT05090345
  A Prospective Registry of Pediatric Cellular Therapy Patients at Risk for Endothelial Dysfunction, Sinusoidal Obstruction Syndrome and/or Multi-Organ Dysfunction Syndrome (MODS).
  Duke University
• ACTIVE NOT RECRUITINGNANCT03865589
  Using Ultrasound Elastography to Predict Development of Hepatic Sinusoidal Obstruction Syndrome
  Children's Mercy Hospital Kansas City

See all trials for Hepatic veno-occlusive disease →